Table 2 Univariate and multivariate analysis for overall survival (OS) for the 304 patients with NPC
Variables | Univariate analysis | Multivariate analysisa | ||||
|---|---|---|---|---|---|---|
HR | 95.0% CI for HR | P value | HR | 95.0% CI for HR | P-value | |
Gender | ||||||
Male vs female | 1.014 | 0.515–1.997 | 0.967 | – | – | – |
Age | ||||||
≤46 years vs > 46 years | 1.458 | 0.814–2.612 | 0.205 | – | – | – |
Tumor stage | ||||||
T1–2 vs T3–4 | 3.17 | 0.976–10.144 | 0.055 | – | – | – |
Node stage | ||||||
N0–1 vs N2–3 | 1.497 | 1.110–2.020 | 0.008 | – | – | – |
TNM stage | ||||||
I vs II vs III vs IV | 2.971 | 1.709–5.165 | <0.001 | 2.190 | 1.234–3.886 | 0.007 |
Treatment | ||||||
Radiotherapy vs chemoradiotherapy | 3.800 | 0.921–15.674 | 0.065 | – | – | – |
CRP (mg/L) | ||||||
≤ 2.03 vs > 2.03 | 3.014 | 1.496–6.074 | 0.002 | – | – | – |
SAA (mg/L) | ||||||
≤ 4.46 vs > 4.46 | 2.956 | 1.555–5.617 | 0.001 | 2.276 | 1.186–4.368 | 0.013 |
PLR | ||||||
≤ 141.52 vs > 141.52 | 1.368 | 0.767–2.440 | 0.289 | – | – | – |
NLR | ||||||
≤ 2.62 vs > 2.62 | 2.361 | 1.260–4.426 | 0.007 | – | – | – |
LMR | ||||||
≤ 1.87 vs > 1.87 | 1.619 | 0.502–5.219 | 0.420 | – | – | – |
EBV DNA (copies/mL) | ||||||
≤ 2340 vs > 2340 | 3.079 | 1.620–5.851 | 0.001 | 2.075 | 1.061–4.060 | 0.033 |